Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study

07:38 AM EDT, 09/15/2026 (MT Newswires) -- Pulse Biosciences (PLSE) said Tuesday that it has completed enrollment in its clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules. The study enrolled 100 patients across three US clinical sites, double the original target of 50 patients, the company said. The first patient completed the final 12-month follow-up last month, it added. Pulse Biosciences said it plans to present preliminary study data at an upcoming medical society conference, with full data expected after all patients complete 12-month follow-up.